Puma Biotechnology
PBYI
198 hedge funds and large institutions have $3.55B invested in Puma Biotechnology in 2015 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 72 increasing their positions, 53 reducing their positions, and 56 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 53
3.49% more ownership
Funds ownership: 91.23% → 94.72% (+3.5%)
1% less funds holding
Funds holding: 199 → 198 (-1)
1% less call options, than puts
Call options by funds: $46.7M | Put options by funds: $47.3M
2% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 56
48% less capital invested
Capital invested by funds: $6.87B → $3.55B (-$3.32B)
86% less funds holding in top 10
Funds holding in top 10: 7 → 1 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$258M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$144M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$107M |
| 4 |
O
OrbiMed
New York
|
+$103M |
| 5 |
CCM
Cornerstone Capital Management
Edina,
Minnesota
|
+$57.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$164M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$84.1M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$76.2M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$71.7M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$52.4M |
PBYI Hedge Fund Activity: Q2 2015 in Review
198 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2015, worth a combined $3.55B — down 48% from $6.87B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of PBYI and 55 opened new positions — a net loss of 1 holder — while 53 trimmed existing stakes and 72 added.
The largest buyer was Grantham, Mayo, Van Otterloo & Co (GMO), opening a new position worth an estimated $258M. The largest seller was T. Rowe Price Associates, cutting an estimated $164M.
- 198 institutional investors held Puma Biotechnology (PBYI) as of Q2 2015, down from 199 in Q1 2015.
- Funds reported $3.55B of Puma Biotechnology stock for Q2 2015, down 48% quarter-over-quarter.
- 55 funds opened new Puma Biotechnology positions in Q2 2015 and 56 closed out, a net change of -1 holder.
- The largest Puma Biotechnology buyer in Q2 2015 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $258M added.
- The largest Puma Biotechnology seller in Q2 2015 was T. Rowe Price Associates, an estimated $164M sold.
Based on aggregated 13F filings for Q2 2015.